Back to All Combinations

MET Amplification + RAS WT

Intermediate Prognosis
2.00% Prevalence C General
Actionable Target
FDA-approved targeted therapies or strong clinical trial evidence available
Genes Involved
MET Amplification RAS Wild-type
Recommended Treatments
MET inhibitors (clinical trials)
Capmatinib
Tepotinib
Treatments to Avoid

No specific contraindications noted

Key Statistics
2.00%
Prevalence in CRC
Yes
Targetable
Clinical Notes
May emerge as resistance mechanism to anti-EGFR therapy. MET inhibitors in development.
Information

Category: General

Evidence Level: C

Related Combinations
Medical Disclaimer: This information is for educational purposes only and should not replace professional medical advice. Always consult with your oncologist for personalized treatment decisions based on your specific situation.